Chikungunya Vaccines

Recently licensed viral vaccines

This page catalogs 2 chikungunya vaccine products. Chikungunya vaccines are among the newest additions to the licensed vaccine portfolio, with both products receiving FDA approval in 2023–2025 for adults at increased risk of exposure.

Last updated: April 2026.

Chikungunya Vaccine Catalog

Trade Name Generic Designation Manufacturer Vaccine Type Regulatory Status & Year Key Notes
IXCHIQ Chikungunya vaccine, live-attenuated (VLA1553) Valneva Live-attenuated viral FDA Licensed, 2023 First chikungunya vaccine approved
VIMKUNYA Chikungunya vaccine, recombinant Bavarian Nordic Recombinant FDA Licensed, 2025 Second US-licensed chikungunya vaccine

Sources

Regulatory data sourced from FDA CBER Vaccines Licensed for Use in the United States (March 2026). Catalog scope informed by Khan, Shaz, The Ultimate Vaccine Timeline.

Related Pages on VaccinationFacts.com

Vaccine Catalog

Browse all vaccine categories

Vaccine History Timeline

Milestones in vaccine development